drugset / Trial / NCT00689078

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078

Phase 4 Completed 36 enrolled ORA, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.

Timeline

Start
2008-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Loteprednol Etabonate Other / unclassified 0.2 % Other
Comparator Prednisolone Other / unclassified 0.12 % Other
Comparator Prednisolone Other / unclassified 1 % Other

Indications